Analyzing NovoCure (NASDAQ:NVCR) & NeurAxis (NASDAQ:NRXS)

NovoCure (NASDAQ:NVCR) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares NovoCure and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
NeurAxis	-492.76%	N/A	-641.25%

Volatility & Risk

NovoCure has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and NeurAxis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35 million	2.50	-$136.23 million	($1.30)	-10.82
NeurAxis	$5.32 million	18.19	-$14.63 million	($0.78)	-9.87

NeurAxis has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NovoCure and NeurAxis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1	4	2	0	2.14
NeurAxis	0	1	1	0	2.50

NovoCure presently has a consensus target price of $21.20, indicating a potential upside of 50.68%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 68.83%. Given NeurAxis’ stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than NovoCure.

Insider & Institutional Ownership

84.6% of NovoCure shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Comparatively, 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

NeurAxis beats NovoCure on 9 of the 14 factors compared between the two stocks.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.